Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 14;11(6):828.
doi: 10.3390/cancers11060828.

Treatment Options for Pancreatic Neuroendocrine Tumors

Affiliations
Review

Treatment Options for Pancreatic Neuroendocrine Tumors

Amit Akirov et al. Cancers (Basel). .

Abstract

The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease. However, many patients present with metastatic and/or advanced local disease. In such instances, the goal of therapy is to control tumor growth and/or decrease tumor burden, lengthen survival, and palliate local symptoms and those of hormone excess. This typically requires a multimodal approach, including surgery, liver-directed treatment, and systemic medical therapy.

Keywords: neuroendocrine tumors; pancreas; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Treatment Algorithm. Suggested treatment algorithm for pancreatic neuroendocrine tumors, based on functionality and localized or metastatic disease.

References

    1. Lawrence B., Bjorn G.I., Anthony C., Bernhard S., Mark K., Irvin M.M. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Endocrinol. Metab. Clin. 2011;40:1–18. doi: 10.1016/j.ecl.2010.12.005. - DOI - PubMed
    1. McKenna L.R., Edil B.H. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3:258–275. - PMC - PubMed
    1. Bartolini I., Bencini L., Risaliti M., Ringressi M.N., Moraldi L., Taddei A. Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. Gastroenterol. Res. Pract. 2018;2018:1–12. doi: 10.1155/2018/9647247. - DOI - PMC - PubMed
    1. Lloyd R.V., Osamura R., Kloppel G., Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th ed. IARC Press; Lyon, France: 2017.
    1. Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 2008;19:1727–1733. doi: 10.1093/annonc/mdn351. - DOI - PMC - PubMed